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Abstract
In skin wound healing the injured tissue goes through a normal progression, 
inflammation subsides and remodeling occurs. However after spinal cord injury 
inflammation persists and there is less progression into a regenerative/rebuilding 
phase. This inflammatory process after spinal cord injury is orchestrated by many 
cell types and numerous cytokines. Although there are several positive effects of 
inflammation after spinal cord injury, such as the removal of debris, the substantial 
upregulation of immune cells has been shown to contribute to neural degeneration. 
Several chemokines and cytokines including many interleukins are involved in guid-
ing these immune cells to the lesion. While there are many inflammatory cytokines 
acting on these immune cells after SCI, there are also several anti-inflammatory 
interleukins that have shown beneficial effects in reducing inflammation. After SCI 
in a rat model, interleukin-10 and interleukin-19 have been shown to downregulate 
the synthesis of pro-inflammatory species including interleukin-1β and tumor 
necrosis factor-α, which resulted in a significant improvement in rat hind limb func-
tion. Also, interleukin-4 and interleukin-13 are related anti-inflammatory cytokines 
that regulate many aspects of inflammation and have also been shown to induce 
alternative macrophage activation. The differing and complex roles interleukins 
play, highlight their importance on the inflammation that persists after spinal cord 
injury. Here we review both the positive effects and negative effects that interleukins 
have during the multifaceted inflammation process following spinal cord injury.
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1. Introduction
Spinal Cord Injury (SCI) is a devastating trauma and according to the National 
Spinal Cord Injury Statistical Center (NSCISC) there are approximately 294,000 
people living with SCI in the United States [1]. After spinal SCI there is immediate 
cell death caused directly from the insult followed by a cascade of inflammation 
that leads to additional cell death and a much larger scar formation that impedes 
axonal regeneration [2, 3]. Although there are several positive effects of inflamma-
tion after SCI, the extensive infiltration of immune cells is a principal contributor to 
neural degeneration [4, 5]. These immune cells are guided to the lesion site from the 
periphery via many signaling cues including several interleukins (ILs) released by 
microglia, astrocytes, and peripheral macrophages within the lesion [5, 6].
Interleukin
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Throughout the first hours after injury, polymorphonuclear leukocytes are 
the predominant infiltrating cells and over-activation of these cells causes tissue 
destruction through the release of significant amounts of neurotoxins including 
reactive oxygen species (ROS), reactive nitrogen species (RNS), chemokines, 
and enzymes [5, 7, 8]. Microglia, the resident macrophages, are also activated and 
migrate to the site of injury, proliferate, and transform from the ramified pheno-
type to amoeboid phagocytic cells [9]. These activated microglia and peripheral 
macrophages make up the majority of inflammatory cells present at the site of the 
lesion. Although in normal wound healing macrophages sequentially change and 
reduce inflammation, after SCI macrophages persist in an inflammatory state for 
prolonged periods resulting in progressive tissue degeneration [10, 11]. However 
these microglia/macrophages can be activated toward an anti-inflammatory pheno-
type and ILs are important signaling cues in the extracellular environment that help 
dictate this contrasting phenotype. The goal of this chapter is to examine the role 
ILs have on the dynamic inflammatory process that occurs after SCI.
2. Interleukins involved in inflammation after SCI
There are numerous known ILs and several of these ILs are shown to be 
involved in inflammation after SCI. Throughout this chapter we will discuss the 
ILs that have been investigated after SCI and whether their role is predominately 
inflammatory or anti-inflammatory. It is important to note, the role an IL plays 
after injury is not as simple as just inflammatory or anti-inflammatory. For many 
of the ILs there are multiple factors that determine whether they will have a 
beneficial role or a detrimental role, including the extent of initial injury, concen-
tration of IL, other associated molecules in the injury, and the response of immune 
cells and glial cells [12, 13].
Although there is a broad spectrum of signaling molecules including cytokines, 
chemokines, and other reactive species after SCI, this chapter will just focus on ILs 
and only the ILs that are known to play a role in inflammation after SCI [14]. These 
ILs will be discussed in terms of the cell types that produce them, receptors they 
bind, cell types they target, timeline of upregulation, and ultimately their effect on 
inflammation after SCI.
2.1 Interleukin-1 family cytokines
IL-1α, IL-1β, and IL-33 are members of the IL-1 family that have been studied 
after SCI and all are predominantly inflammatory [15]. IL-1 is released via activated 
macrophages and microglia largely in response to disease, infection, or inflamma-
tory events. IL-1 has two structurally and biologically similar isoforms, IL-1α and 
IL-1β [13]. These two isoforms share roughly 30% amino acid sequence homology 
and although they perform similar biological functions, IL-1β plays a more substan-
tial role post-SCI [16, 17]. IL-1β has been shown to contribute to the exaggerated 
neuroinflammation following SCI that leads to secondary neural degeneration and 
cell death [16]. IL-1 signaling following SCI is diverse and complex, resulting in 
a recruitment of neurotoxins or immune system molecules that contribute to the 
inflammatory response [13].
The primary receptor for signaling of both IL-1 isoforms is the type-I inter-
leukin-1 receptor (IL-1RI). IL-1 signaling is further regulated by a decoy receptor 
(IL-1RII) and a receptor antagonist (IL-1ra) [13]. The expression of these recep-
tors mediates the inflammatory response to SCI and their mechanisms have been 
widely studied following SCI. After SCI in rats, IL-1R1 expression is elevated as 
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early as 4 hours, peaks at 8 hours to 1-day and remains elevated for 7 days post-
injury [13]. Another study tested the role of IL-1ra as a regulatory molecule follow-
ing SCI and observed that increased expression of IL-1ra suppressed IL-1β levels 
and increased locomotor function following SCI, suggesting that IL-1β and IL-1RI 
play critical roles in secondary tissue damage and impaired functional recovery 
post-SCI [16]. Likewise, administration of IL-1β suppressed the expression of 
IL-1ra following SCI indicating the regulatory nature of IL-1β interactions with 
its receptor antagonist [16]. Similarly, a study using IL-1 knockout mice observed 
a significantly smaller lesion area and improved locomotor function after SCI in 
comparison to wild-type mice [18].
The signaling cascade of the IL-1β/IL-1RI pathway is complex and yet to be 
completely understood, however it is widely understood that it stimulates the 
production of toxic intermediates that cause neural degeneration and cell death 
[13]. These toxic inflammatory mediators include prostaglandins, cyclooxygenase 
2, and phospholipase A2 [13]. However, there are studies showing benefits of IL-1, 
where IL-1β null mice failed to remyelinate as rapidly as wild-type mice [19]. These 
different roles IL-1 plays are likely due to several factors including extent of injury 
as well as IL-1 concentration and timing of upregulation, but at present are not well 
understood.
Another member of the IL-1 family, IL-33, predominantly induces type-2 
immune responses against allergens and infectious diseases [20]. IL-33 is upregu-
lated in response to SCI and tends to localize in spinal cord astrocytes to reduce 
T cell infiltration and overexaggerated inflammation that leads to neuronal cell 
death [21]. IL-33 is classified as an alarm signal (alarmin) and is released by epi-
thelial cells upon signals of cell or tissue death, but the exact in vivo mechanism of 
release is not fully understood [22]. After its release, IL-33 binds to ST2 receptors 
(IL-1RL1) that are present on multiple immune cells as an alert signal for immuno-
logic and neurologic damage or inflammation [22].
One study that treated SCI injury in mice with administration of recombinant 
IL-33 indicated an attenuation of spinal cord encephalomyelitis progression and 
a significant decrease in neural tissue death, decrease in demyelination, and an 
overexaggerated astrocyte infiltration at the lesion site of the contused spinal 
cord [21]. These results yielded a significant increase in functional recovery and 
a dramatic decrease of the expression of TNF-α in the spinal cord for as long 
as 42 days post-SCI. In addition to suppression of pro-inflammatory cytokine 
release, IL-33 administration promoted the activation of anti-inflammatory M2 
macrophage/microglia [21].
2.2 Interleukin-2 family cytokines
Cytokines from the IL-2 family, IL-2, IL-4, IL-7, IL-15, and IL-21, all share a 
common receptor subunit (gammac), which plays a major role in promoting and 
maintaining T lymphocyte populations [23]. IL-2 is a pro-inflammatory cytokine 
made up of four α helixes and is produced mainly by CD4+ cells when activated. 
At an mRNA level, signals from T-cell receptor (TCR) and CD28 closely regulate 
the production of IL-2 [24]. After synthesis, IL-2 binds to a receptor complex, 
which consists of three subunits, IL-2Rα, IL-2Rβ, and the common γ-chain [24]. 
All three subunits are needed to achieve high affinity binding. These receptors are 
located on regulatory T cells and antigen-activated T lymphocytes [25]. To produce 
an IL-2-dependent response, IL-2 must be produced and IL-2R must be expressed 
within the same microenvironments [25].
IL-2 and its receptor, IL-2R, are crucial to maintaining the balance of the timing 
and adequacy of an immune response [26]. The primary role of IL-2 is to perpetuate 
Interleukin
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the proper response of memory T-cells to invading pathogens [27]. In addition, IL-2 
is vital to the survival, as well as death, of lymphocytes, which has an effect on the 
development of the immune system. By properly maintaining the life of regulatory 
T cells (T reg) and activation-induced cell death, IL-2 is able to eliminate self-
reactive T cells as a preventative measure against autoimmune diseases [27]. After 
SCI in a rat, IL-2 levels were significantly lower than intact controls from 3 days to 
2 weeks post-SCI [14]. In addition, the interaction of IL-2 with its receptor after 
SCI contributes to the proliferation of T-helpers, which also have an effect on the 
proliferation of cytotoxic T cells, natural killer cells, lymphokine-activated killers, B 
cells, and macrophages [14].
IL-4 and IL-13 are related anti-inflammatory cytokines that regulate many 
aspects of inflammation and have also been shown to induce alternative macro-
phage activation (Figure 1) [28]. IL-4 is a cytokine that is involved in regulating 
immunity, and is secreted by Th2 cells, eosinophils, basophils, and mast cells 
[29]. IL-4 is also involved in allergic inflammation by utilizing Th2 lymphocytes, 
differentiated from Th cells, which can then be used in the production of effector 
cytokines [30]. IL-4 binds to its receptor IL-4Rα, and will dimerize with either 
γc (the common cytokine-receptor γ-chain) and produce the type-1 signaling 
complex, or with IL-13Rα1 and produce the type-2 signaling complex (Figure 1) 
[29, 31]. Although IL-4 has a major impact on immunity, it also affects cognition 
based on T-cells mediated by IL-4. When administered within a short period 
post injury, IL-4 exhibits anti-inflammatory effects; however, it can exert a 
pro-inflammatory response when macrophages possessing IL-4 are undergoing 
pro-inflammatory stimulation [29].
Lima et al. (2017) performed a study to understand the effect of the acute and 
sub-acute treatment using IL-4 on various populations of neural cells and on func-
tional recovery in vivo. In the injured spinal cord, treatment using a systemic deliv-
ery of IL-4 (0.35 μg/kg) for 7 days, led to an upregulation of the anti-inflammatory 
Figure 1. 
IL-4, IL-13, and IL-10 pathways and effects.
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IL-10 and a reduction in area of macrophage/microglia expressing inflammation 
markers CD11b and inducible nitric oxide synthase (iNOS) [32]. After systemic 
IL-4 treatment, they also observed an increase in the number of O4-positive cells 
(a marker for both type I and type II oligodendrocytes) and neuronal markers 
βIII-tubulin and NeuN, suggesting that IL-4 has a role in neuroprotection. This 
overall reduction in inflammation resulted in improved hind limb function in rats 
after SCI. Although they observed several positive effects, systemic IL-4 did not 
have an effect on the number of astrocytes or lesion size [32]. In another study a 
delayed intraspinal injection of IL-4 (100 ng of recombinant IL-4, 48 hours after 
injury) was given after a spinal cord contusion in mice [33]. The intraspinal injec-
tion of IL-4 resulted in an increase in microglia/macrophages expressing antigens 
characteristic of an anti-inflammatory M2 phenotype, reduced tissue damage, 
and improved hind limb function in mice after SCI [33]. These studies suggest 
that therapies using IL-4 could be a valuable treatment for improving function 
after SCI.
IL-13 is produced by different T cell subsets, dendritic cells, and activated Th2 
cells [34]. Although the IL-13α2 receptor was originally thought to be a “decoy” 
receptor that serves as a neutralizer (Figure 1) [35], Fichtner-Feigl et al. showed a 
role for IL-13Rα2-mediated signaling that required the cytoplasmic tail of IL-13Rα2 
in the production of transforming growth factor beta (TGF-β), an anti-inflammatory 
shown to down-regulate inflammatory cytokines, providing evidence for IL -13Ra2-
mediated signaling (Figure 1) [31, 36]. Furthermore, after SCI it was shown that 
transplanted mesenchymal stem cells continuously expressing IL-13 improved func-
tional recovery and decreased lesion size. In addition, IL-13 increased the amount of 
ARG-1-expressing macrophages [37].
IL-7 is a homeostatic cytokine that plays a key role in the survival of multiple 
immune cells and acts on lymphocytes [38]. The IL-7 receptor complex is composed 
of two chains, IL-7Rα and γc (the common cytokine-receptor γ-chain), which 
signal downstream to the JAK/STAT5 pathway, and assists in regulating the sur-
vival and development of immune cells [38]. IL-7 is produced by stromal cells in 
lymphoid organs and is necessary for T-cell development and their survival in the 
periphery [39].
After SCI in mice, IL-7 is promptly upregulated and displays as a strong chemo-
tactic property for macrophages [40]. An intraspinal injection of IL-7 after SCI in 
mice, resulted in an increase in pro-inflammatory cytokines IL-1β, IL-6, and TNF-
α, and a decrease in the anti-inflammatory cytokine IL-10 [38]. The increase in IL-7 
also led to an increase in apoptosis, macrophage infiltration, and a decrease in hind 
limb function in mice after SCI [38]. Moreover, blocking the IL-7 receptor after SCI 
in mice, resulted in suppression of pro-inflammatory cytokines IFN-γ and TNF-α, 
an increase in IL-4 and IL-13, more macrophages expressing antigens characteristic 
of an anti-inflammatory M2 phenotype, an increase in spared white matter, and 
an improvement in hind limb function [40]. During SCI, the JAK/STAT5 pathway 
is activated, and IL-7 post-SCI also contributes to the activation of the JAK/STAT5 
pathway, which upholds a crucial role in the inflammatory response and secondary 
damage [38]. When the JAK/STAT5 pathway was inhibited by pimozide, the effects 
of IL-7 discontinued, which emphasizes the relationship between the JAK/STAT5 
pathway and IL-7 function [38]. Therefore, Yuan et al. (2019) concluded that the 
IL-7/JAK/STAT5 axis targeted by antagonists may represent a potential therapeutic 
treatment for SCI [38].
Similar to IL-2, IL-15 is a pro-inflammatory cytokine that is also part of the 
four α helix cytokine family. The main function of IL-15 is to provide a long-term 
immune response to invading pathogens by contributing to the homeostasis of 
natural killer cells and CD8+ memory T cells that express IL-2/IL-15Rβ and γc [27]. 
Interleukin
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IL-15 has three receptors, IL-15Rα, IL-2Rβ, and γc, and shares two of the receptors 
with IL-2 (IL-2Rβ and γc) [41]. Although IL-15 has not been well studied after SCI, 
it has been shown to be involved in the development of neuropathic pain from nerve 
injury [42]. After sciatic nerve injury, IL-15 expression was observed in the spinal 
cord in astrocytes and microglia, and it is also present in neurons located in the 
dorsal and ventral horn [42].
IL-21 is a pleiotropic cytokine expressed by many immune cells including 
natural killer T cells and activated CD4+ T cells [43]. Similar to other inflamma-
tory mediators, IL-21 is upregulated after SCI [44, 45]. Fu et al. (2017) studied 
peripheral blood-derived mesenchymal stem cells (PBMSCs) as a therapy for SCI 
and their role in the lesion microenvironment by analyzing the neuroprotection, 
differentiation, and immunoregulation of PBMSCs that were engrafted. When 
IL-21 was inhibited, a decrease in the secretion of IL-23a and IL-22 occurred 
[44]. When investigating the potential Th17/Treg-relative mechanism of PBMSCs 
therapy after SCI, Fu et al. (2017) discovered that the M1 macrophage migrated to 
lesion site and resulted in the pro-inflammatory secretion of IL-6 and IL-21, which 
led to CD4 + T cells differentiating into CD4 + IL17 + Th17 cells [44]. Furthermore 
it has been shown that IL-17 production is stimulated by the combination of IL-21 
and TGF-β [45].
2.3 β common chain cytokines IL-3, and IL-5
The β common cytokine family, including IL-3 and IL-5, is defined by a shared 
receptor structure, comprising of a specific α chain and a common β chain that is 
essential for cytokine-specific receptor signaling [46]. IL-3 is a cytokine that is 
produced by activated T cell lymphocytes, which then induces the production of 
various hematopoietic cell types that are crucial to the immune response [47]. IL-5 
is cytokine that is produced by hematopoietic and non-hematopoietic cells, includ-
ing granulocytes, T cells, and natural helper cells [48]. IL-5 is also a mediator for 
eosinophilic inflammation by providing stimulation, differentiation, recruitment 
and activity of eosinophils. Due to their roles with eosinophils, IL-3 and IL-5 have 
been primarily studied in asthma, and their roles after SCI are not clear. However, 
both of them co-express in TH2 cells, which is a subset of CD4+ cells. These TH2 
cells are characterized by the production of IL-4, IL-5, IL-10 and IL-13 and thus, 
may be beneficial in exerting anti-inflammatory effects after SCI [49, 50].
2.4 IL-6 and IL-11
IL-6 and IL-11 are grouped into one cytokine family because the receptor 
complex of each cytokine contains two of the signaling receptor subunit gp130 
(Figure 2) [51]. For both IL-6 and IL-11 there are membrane bound receptors as well 
as soluble receptors and after ligand binding to either the membrane bound receptor 
or the soluble receptor, they form a complex with two gp130 receptors leading to Jak/
STAT pathway signaling (Figure 2) [52, 53].
IL-6 is predominantly an inflammatory cytokine. After SCI in a mouse model, 
Pineau et al. observed IL-6 mRNA expression in astrocytes, microglia/ macro-
phages, and neurons, starting at 3 hours post-injury, peaking at 12 hours and con-
tinuing for 4 days post-injury [54]. Similarly after SCI in humans IL-6 is strongly 
upregulated. IL-6 levels in cerebrospinal fluid of SCI patients changed from unde-
tectable (<4 pg./ml) in non-injured controls to an average of almost 30,000 pg./mL 
in the subset of patients with complete SCI [55]. Furthermore, the cerebrospinal 
levels of IL-6 correlated with the extent of spinal cord damage in humans, which 
demonstrates the importance of IL-6 after SCI.
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IL-6 leads to recruitment of immune cells. Delivery of IL-6/sIL-6 receptor 
fusion protein to injury sites induced a sixfold increase in neutrophils and a twofold 
increase of macrophages/microglial [56]. Mice treated with an antibody against 
IL-6 receptor showed a reduction in neutrophil and monocyte/macrophage inva-
sion [57, 58]. It was also shown that blocking IL-6 signaling after SCI reduces the 
damaging inflammatory activity by promoting the formation of alternatively 
activated M2 macrophages [59]. Taken together these data suggest IL-6 signaling is 
an activator of inflammation and a strong recruiter of immune cells after SCI.
After SCI astrocytes proliferate and migrate to the injury leading to a dense 
astroglial scar surrounding the lesion. It has been shown in vitro that IL-6 signaling 
acts on neural stem cells to induce their differentiation into astrocytes [60]. This 
was supported by several in vivo studies including, IL-6 knockout mice that showed 
suppression of astrogliosis following SCI [61], mice with an excessive expression of 
IL-6 and IL-6R showed abundant astrogliosis suggesting that astrocytes were selec-
tively affected in these mice [62], and the development of astrogliosis was inhibited 
in mice given an IL-6 receptor blocker after SCI [58].
Several studies have shown that blocking IL-6 signaling improves functional 
recovery after SCI [57–59]. It has also been shown that delivery of IL-6/IL-6 recep-
tor resulted in a four fold decrease in axon growth [56]. However there are studies 
showing that IL-6 is neuroprotective and aids in axonal regeneration [63, 64]. 
The differences in IL-6 effect may depend on the level of expression and timeline 
of IL-6 upregulation. The studies using an IL-6 blocker were performed in the 
sub-acute timeframe after SCI. In the sub-acute SCI, any neurotrophic effects of 
IL-6 appear to be overwhelmed by its proinflammatory features. Taken together, 
the aforementioned data demonstrates the importance of IL-6 after SCI. IL-6 
upregulates inflammatory cytokines, recruits immune cells, effects macrophage 
phenotype, effects astrocyte activation, effects axonal regeneration, and effects 
functional recovery.
IL-11 has been shown to be primarily anti-inflammatory. Recombinant 
IL-11 administered to activated macrophages inhibited the production of pro-
inflammatory cytokines TNF-α, IL-1β, IL-12, and nitric oxide production [65–67]. 
Furthermore, IL-11 has been shown to play an anti-inflammatory role in the 
airways for asthma [68], play a role in decreasing mucosal damage in inflammatory 
bowel disease [69], and importantly IL-11 has a neuroprotective role in multiple 
sclerosis [70]. Due to these anti-inflammatory roles, Cho et al. analyzed the role of 
IL-11 after SCI using IL-11Rα knockout mice [71]. In wild type mice, they observed 
Figure 2. 
Classic and trans-signaling. Cells that express the IL-6R or IL-11R will undergo classic signaling when IL-6 
or IL-11 bind to the corresponding receptor, inducing gp130 dimerization and initiating intracellular signal 
transduction. Trans-signaling occurs when the ligand and soluble receptor complex (IL-6/sIL-6R or IL-11/sIL-11R) 
associate with gp130 inducing gp130 dimerization and initiating intracellular signal transduction.
Interleukin
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a significant upregulation in IL-11 with a peak gene expression 24 hours after injury 
and a significant upregulation of IL-11Rα at 3 and 7 days after SCI. Somewhat 
surprisingly, they did not observe significant differences in functional recovery or 
histopathology in IL-11Rα knockout mice as compared to wild type mice after SCI. 
The authors speculate that since “the peak in IL-11Rα expression is on the order of 
days after SCI, suggests that IL-11 signaling may not play as significant a role in the 
acute inflammatory response after injury, but more in the long-term sequelae such 
as oligodendrocyte survival”. Maheshwari et al. used a cuprizone induced mouse 
model of demyelination in the central nervous system to analyze the effects of over-
expression of IL-11 on demyelination/remyelination [72]. Overexpression of IL-11 
was able to limit cuprizone-induced demyelination by reducing oligodendrocyte 
cell death, decrease microglial activation, and enhance spontaneous remyelination. 
Maheshwari’s results further suggest that IL-11 likely plays a role in the long-term 
remyelination efforts after SCI and is not as involved in the sub-acute stage [72].
2.5 Interleukin-8 and interleukin-16
IL-8, also known as neutrophil chemotactic factor or CXCL8, primarily induces 
chemotaxis in neutrophils and granulocytes. IL-8 is a member of the chemokine 
family that acts on CXCR1 and CXCR2 receptors (il8ra and il8rb, respectively), which 
have been primarily studied on polymorphonuclear leukocytes. However many other 
cell types express these receptors including neurons [73]. Several studies have shown 
that IL-8 can be released by a wide variety of cells including monocytes endothelial 
cells, T lymphocytes, and macrophages [73]. After SCI in rat, GRO, the rat analogue of 
human IL-8, is strongly upregulated for at least 14 days and the upregulation of GRO 
strongly correlates with the extent of injury [14, 74, 75]. Furthermore IL-8 is upregu-
lated in the cerebrospinal fluid of dogs and humans after SCI, and for humans the 
IL-8 levels are also shown to correlate with the extent of damage [55, 76, 77]. Although 
IL-8 clearly plays a role in neutrophil infiltration and overall inflammation after SCI, 
as shown by its significant upregulation, it has not been extensively studied after SCI.
IL-16 is a proinflammatory cytokine that is produced by mast and leukemic cells, 
fibroblasts, endothelial cells, granulocytes, dendritic cells, CD4+ and CD8+ T lympho-
cytes, monocytes, and microglial cells. IL-16 plays a role in the release of other proin-
flammatory cytokines (IL-1β, IL-6, IL-15, and TNFα), the increase of intracellular Ca++ 
or inositol-(1,4,5)-triphosphatase, and the translocation of protein kinase C [78]. These 
processes occur after IL-16 binds to the signal-transducing CD4 receptor molecule [79]. 
Moreover, IL-16 promotes lymphocyte migration and modulates apoptosis [80].
Following spinal cord injury, IL-16 plays a role in recruiting and activating 
inflammatory cells. Microglia that produce IL-16 migrate to the lesion site and 
other areas of significant neuronal damage [78]. Following neuroinflammation, it is 
suggested that IL-16 microglia are one of the first cells to respond [80]. In addition, 
macrophages with IL-16 remained present at the injury site for up to thirty days 
post injury, indicating long-term IL-16 function [78]. One study found that expres-
sion of IL-16 in microglia and macrophages is induced by the IL-12 p40 homodimer 
through IL-12Rβ1, but not IL-12 p70 [80]. Overall, the ability of IL-16 to quickly 
recruit microglia/macrophages to the lesion site following SCI results in increased 
neuronal damage and microvessel clustering [78].
2.6 Interleukin-10 family cytokines
Members of the IL-10 family of cytokines that have been studied after SCI 
include, IL-10, IL-19, IL-20, and IL-22 [81]. IL-10 is an anti-inflammatory cyto-
kine that is produced by monocytes, B cells, dendritic cells, natural killer cells, 
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and T cells [82]. In leukocytes, IL-10 acts on both innate and adaptive immune 
cells with a wide range of immunomodulatory activities that suppress prolifera-
tion, cytokine secretion, and costimulatory molecule expression of proinflamma-
tory immune cells. The IL-10 receptor consists of heterotetramer complex made 
of two IL-10R1 molecules, encoded by the IL10ra gene, and two IL-10R2 mol-
ecules, encoded by the IL10rb gene (Figure 1) [83]. IL-10 downregulates several 
pro-inflammatory cytokines and inflammatory species [11]. In addition, IL-10 
can affect T cell and natural killer cell function indirectly and directly through 
connection with monocytes and macrophages. The overall impact of IL-10 is 
determined by the timing and site of its production, which are both affected by 
which cells are making IL-10. Since IL-10 production by one cell type affects 
the ability of other cells to make IL-10, IL-10-producing cells show potential to 
regulate each other [82].
Following SCI, IL-10 downregulates pro-inflammatory molecules IL-1β, IL-2, 
IL-6, TNF-α, IFN-γ, matrix metalloproteinase-9, nitric oxide synthase, myeloper-
oxidase, and reactive oxygen species. IL-10 also provides trophic support to neurons 
through downregulation of pro-apoptotic factors cytochrome c, caspase 3, and Bax, 
as well as upregulation of anti-apoptotic factors B cell lymphoma 2 (Bcl-2) and Bcl-
2-associated X, B-cell lymphoma-extra large (Bcl-xl) (Figure 1) [11]. There have 
been several studies performed to test IL-10’s therapeutic value as a treatment for 
SCI. Although these studies used a variety of different systemic and local methods 
to administer IL-10 after SCI, the majority of results showed strong positive effects 
from the IL-10. These positive effects after SCI include a reduction in pro-inflam-
matory molecules, macrophages expressing more antigens characteristic of an 
anti-inflammatory M2 phenotype, reduced lesion size, and an improvement in hind 
limb function [11, 84].
IL-19 is produced by monocytes and microglia, and binds to the IL-20 receptor 
complex, which consists of IL-20R1 and IL-20R2 chains [85]. Activated microglia 
upregulate IL-19 and express the IL-20 receptor complex [86]. It has also been 
shown that ablation of IL-19 in activated microglia increased the production of 
pro-inflammatory cytokines IL-6 and TNF-α, which demonstrates that IL-19 is 
predominately an anti-inflammatory cytokine in the central nervous system [86].
After SCI in mice, IL-19, IL-20R1 and IL-20R2 are upregulated [87]. In a series 
of four different experiments, mice with spinal cord injuries were treated with 
IL-19 [87]. As a result, Th2 cytokine synthesis was promoted, which polarized 
spinal microglial cells to an M2 phenotype. This helped resolve the inflammation, 
preserving myelin, neurons, and neuronal function. Overall, IL-19 attenuated mac-
rophage accumulation, reduced protein levels of TNF-α and CCl2, promoted Th2 
response and M2 macrophage activation, promoted angiogenesis by upregulating 
VEGF, upregulated HO-1 expression, and decreased oxidative stress in the injured 
region [87].
IL-20 is a proinflammatory cytokine that is predominately produced by mono-
cytes and skin keratinocytes. IL-20 signals through both the IL-20R1/IL-20R2 
heterodimer complex and the receptor complex composed of IL-22R1 and IL-20R2 
[85]. Following spinal cord injury, IL-20 and its receptors are expressed in neurons, 
astrocytes, oligodendrocytes, and microglia in large amounts. IL-20 upregulates 
glial fibrillary acidic protein (GFAP), TGF-β1, TNF-α, MCP-1, and IL-6 expression, 
which stimulates astrocyte reactivation and migration [88]. As a result, glial scar 
border formation is enhanced. Moreover, IL-20 inhibits neuron outgrowth through 
upregulation of Sema3A/NRP-1 in PC-12 cells [88]. The overall result is irreversible 
neuronal loss and glial scar formation post-SCI. In vivo, anti-IL-20 mAb reduces the 
IL-20 inflammatory response, which improves motor and sensory functions, spinal 
cord tissue preservation, and reduces glial scar formation [88].
Interleukin
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2.7 Interleukin-12 family cytokines
The IL-12 family is comprised of 4 members, IL-12, IL-23, IL-27 and IL-35 and 
each member is composed of α-subunit with a helical structure similar to type 1 
cytokines and a β-subunit structurally related to the extracellular regions of Type 1 
cytokine receptors [89]. However from this family of 4 cytokines, only the pro-
inflammatory cytokine IL-12 has been assessed after SCI. IL-12 is produced by 
dendritic cells, macrophages, monocytes, neutrophils, microglia cells, and B cells 
[90]. The IL-12 receptor is made up of IL-12Rβ1 and IL-12Rβ2 chains [91]. IL-12 is a 
heterodimeric molecule, p70, formed from p40 and p35 chains. IL-12p70 is consid-
ered to be the biologically active cytokine that expresses nitric oxide synthase and 
TNF-α in microglia and macrophages. In T cells, p70 interacts with both IL-12Rβ1 
and IL-12Rβ2. However, p70 treatment results in IL-16 mRNA inhibition due to 
inability to induce IL-16 promoter [80].
Yaguchi et al., administered IL-12 after SCI in mice and observed an increase 
in the number of activated macrophages and dendritic cells surrounding the lesion 
site and an increase in the expression of brain-derived neurotrophic factor adjacent 
to the injury. After IL-12 treatment, immunohistochemical analyses revealed that 
de novo neurogenesis and remyelination occurred. The mice treated with IL-12 also 
had a significant improvement in hind limb function [92].
2.8 Interleukin-17 family cytokines
IL-17 cytokines play important roles in both innate and adaptive immunity. 
IL-17A to IL-17F are highly conserved at the C terminus, and contain five spatially 
conserved cysteine residues that mediate dimerization [93, 94]. IL-17A and IL-17E 
have been identified and studied for the roles they play after SCI.
IL-17A is an important cytokine in regard to protective mechanisms against 
infectious diseases and inflammatory pathology within the immune system [95]. 
IL-17A is secreted by a multitude of cells including T cells, dendritic cells, and 
macrophages among others and binds to the A and C subunits of the IL-17 receptor 
to initiate signaling [95]. After SCI in rats, IL-17A is upregulated as early as 1 hour 
after injury, peaks at 24 hours, and remains above normal levels for at least 72 hours 
after injury [45]. This upregulation of IL-17 does appear to play a degenerative 
role on SCI recovery after a study was conducted using IL-17 knockout mice. IL-17 
knockout mice showed increased locomotor function and decreased lesion size after 
SCI, which suggests that IL-17 expression regulates secondary degeneration of the 
neural tissue at the lesion site [96]. Recruitment of immune cells such as B cells, 
neutrophils, and dendritic cells were downregulated at 6 weeks following SCI [96].
Interleukin-25, also known as Interleukin-17E, is in the IL-17 family and binds 
to the heterodimer complex of IL-17A and IL-17-B receptor subunits. IL-25 has 
primarily been understood as a systemic type-2 inflammatory mediator that 
triggers significant helper T-cell expression and proinflammatory cytokine suppres-
sion, however its response following spinal cord injury is largely unknown. IL-25 
is primarily derived from epithelial cells and macrophages in response to infection 
or inflammation and contributes to type-2 helper T cell (Th-2) activation [97]. Th2 
cells are responsible for the release of anti-inflammatory cytokines IL-4, IL-5, and 
IL-13 which play a role in neural protection and regeneration against inflammation 
and neurotoxins [97].
The trafficking mechanism and inflammatory response of IL-25 post-SCI 
remains relatively unclear, but local injection of IL-25 into the lesion site post-SCI 
yields interesting and contradictory results. The local administration of IL-25 
following spinal cord injury in 10-week old mice results in decreased locomotor 
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function, an increase in lesion size, and neuronal demyelination which contradicts 
the systemic immune response upon an IL-25 presence [97]. Interestingly, the 
systemic administration of IL-25 show ineffective results in regard to improved 
functional mobility following spinal cord injury. Microglia and astrocytes survival 
are also unaffected upon injection of IL-25 suggesting that IL-25 indirectly activates 
inflammatory molecules associated with these immune events [97]. These results 
raise questions about the precise role of IL-25 after SCI and possible therapeutic 
interventions using IL-25.
3. Conclusions
Although significant progress has been made in terms of spinal stabilization and 
medical care of patients after SCI, there has not been much progress made in terms 
of treatments for SCI to retain or regain the function that is lost. In order to design 
treatments for SCI, a better understanding of the inflammation process is crucial. 
As outlined in this chapter ILs are an intricate player in inflammation after SCI. For 
some of these ILs, there timeline of involvement and roles they play in inflamma-
tion has been defined. However, there is still much more research that needs to be 
completed to understand the roles many of these ILs play. Along with understand-
ing the current ILs, there will assuredly be more signaling cues discovered that are 
involved after SCI.
Could inflammation be modulated to retain or regain a significant amount of 
function after SCI? This is a fundamental question that needs to be addressed. As 
highlighted in rodent models, such as what is observed in IL-17 knockout mice or 
treatments with anti-inflammatory cytokines, modulating inflammation is a prom-
ising approach for treating SCI. However it is important to realize that all variables 
including age, sex, level of injury, and force to cause the trauma, are controlled 
in these rodent models, and thus treating human SCI will be more challenging. 
These facts highlight the essential need to conduct more research on inflammation 
after SCI.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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